DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

This study will treat patients with CLL/SLL whose disease comes back or is not responding to prior therapy, or if they can not bear side effects of the prior treatment. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body.

Trial Details

NCT ID
NCT06539182
Phase
PHASE2
Sponsor
Dizal Pharmaceuticals
Status
RECRUITING
Cancer Type
Chronic Lymphocytic (CLL) Leukemia
Interventions
  • DZD8586
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Guangzhou, Guandong, China|23.11667,113.25
  • Guangzhou, Guandong, China|23.11667,113.25

Key Eligibility Criteria

  • Participants who meet all the following criteria:
  • Male and female ≥ 18 years of age.
  • ECOG performance status 0-2.
  • Confirmed diagnosis of CLL/SLL with indication for treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Chronic Lymphocytic (CLL) Leukemia Trials on Trialify →